Biotech Values

[DewDiligence]

MNTA—this is why i think the stock price is capped now. thx - i'm going to pass on this one.

The news in #msg-116493180 makes it less likely that Teva’s 40mg patents will hold up; if they don’t, MNTA could launch a 40mg Copaxone generic (with FDA approval) as soon as Jan 2017, when Teva’s Hatch-Waxman exclusivity on the 40mg dose expires (http://www.accessdata.fda.gov/scripts/cder/ob/docs/patexclnew.cfm?Appl_No=020622&Product_No=003&table1=OB_Rx ).

p.s. I added to MNTA today (#msg-116484269).